ArticleProstate cancer and prostatic diseases2018
Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.
Article in Prostate cancer and prostatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- The role of lipid-lowering drugs in urologic and male reproductive cancers: a Mendelian randomization study.Translational andrology and urology · 2026Article
- The prevalence of dyslipidemia in patients with prostate cancer.Prostate international · 2025Article
- Article
- IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth.Oncogene · 2024Article
- Lipid-lowering drugs and cancer: an updated perspective.Pharmacological reports : PR · 2024Review
- Defining cellular population dynamics at single-cell resolution during prostate cancer progression.eLife · 2022Article
- Rhenium(I) conjugates as tools for tracking cholesterol in cells.Metallomics : integrated biometal science · 2022Article
- The effect of lowering cholesterol through diet on serum prostate-specific antigen levels: A secondary analysis of clinical trials.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level.Cancers · 2022Article
- Ezetimibe and Cancer: Is There a Connection?Frontiers in pharmacology · 2022Review
- Worldwide flavor enhancer monosodium glutamate combined with high lipid diet provokes metabolic alterations and systemic anomalies: An overview.Toxicology reports · 2021Review
- The Crosstalk between Prostate Cancer and Microbiota Inflammation: Nutraceutical Products Are Useful to Balance This Interplay?Nutrients · 2020Review
- The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients undergoing resection for colorectal cancer.Scientific reports · 2020Article
- 27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.Molecular cancer research : MCR · 2020Article
- Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Influence of Diet and Nutrition on Prostate Cancer.International journal of molecular sciences · 2020Review
- Effect of inhibiting ACAT-1 expression on the growth and metastasis of Lewis lung carcinoma.Oncology letters · 2019Article
- Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundSome, but not all, epidemiologic evidence supports a role for cholesterol, the precursor for steroid hormone synthesis, in prostate cancer. Using a PTEN-null transgenic mouse model of prostate cancer, we tested the effect of modifying serum cholesterol levels on prostate tumor development and growth. We hypothesized that serum cholesterol reduction would lower tumor androgens and slow prostate cancer growth.
methodsPTEN
resultsEzetimibe-treated mice had lower serum cholesterol at 4 months (p = 0.031). Serum cholesterol was positively correlated with prostate weight (p = 0.033) and tumor epithelial proliferation (p = 0.069), and negatively correlated with tumor epithelial apoptosis (p = 0.004). Serum cholesterol was unrelated to body weight (p = 0.195). Tumor stromal cell proliferation was reduced in the ezetimibe group (p = 0.010). Increased serum cholesterol at 4 months was associated with elevated intraprostatic DHEA, testosterone, and androstenedione (p = 0.043, p = 0.074, p = 0.031, respectively). However, cholesterol reduction did not significantly affect adenocarcinoma development at 2, 3, or 4 months of age (0, 78, and 100% in ezetimibe-treated vs. 0, 80, and 100% in mice not receiving ezetimibe).
conclusionsThough serum cholesterol reduction did not significantly affect the rate of adenocarcinoma development in the PTEN-null transgenic mouse model of prostate cancer, it lowered intraprostatic androgens and slowed tumor growth. These findings support a role for serum cholesterol in promoting prostate cancer growth, potentially via enhanced tumor androgen signaling, and may provide new insight into cholesterol-lowering interventions for prostate cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.